RedHill Biopharma (NASDAQ:RDHL) reported its full-year 2025 financial results and operational highlights on Monday, April 27, 2026, marking a year of significant portfolio high-grading and successful litigation.
The specialty biopharmaceutical company emphasized its transition toward a more streamlined commercial model centered on its flagship product, Talicia, and high-value R&D assets.
Commercial performance was led by Talicia, an all-in-one oral capsule for H. pylori infection.
The product generated approximately $8.9 million in U.S. net revenues, complemented by an additional $1.9 million from markets outside the U.S.
RedHill's strategic partnership with Cumberland Pharmaceuticals was further solidified via a $4 million investment from Cumberland into Talicia Holdings, providing dedicated capital to support the drug’s continued growth trajectory.
On the development and licensing front, RedHill secured a major agreement for RHB-102 (an investigational anti-emetic), with potential milestones reaching up to $60 million.
This deal serves to non-dilutively monetize the company’s R&D pipeline while allowing management to focus on core commercial operations.
Additionally, the company secured a significant legal win with a final $10.5 million judgment from the New York Supreme Court in its favor, providing a substantial boost to its financial standing.
The company concluded the fiscal year with $4.1 million in cash and cash equivalents and a positive equity position of $4.3 million.